The Methanesulfonamide Group: Bright and Dark Sides of hERG Potassium Channel Inhibition
Pharmaceuticals · 01.06.2026 · 19 (6) · 882
DOI: 10.3390/ph19060882 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 01.06.2026. Verfasst von Zsigmond Máté Kovács und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Office, National Research Development and Innovation Office, National Research, Development and Innovation Fund.
Abstract (Originalsprache)
Our review focuses on methanesulfonamide-containing compounds, a well-characterized class of high-affinity blockers of the hERG potassium channel, which plays a critical role in cardiac repolarization by mediating the cardiac IKr. These compounds, which include notable class III antiarrhythmic drugs such as dofetilide and d-sotalol, block the hERG channel in its open state by binding within the inner vestibule. This interaction is particularly strong with some residues and the compounds form hydrogen bonds with others. This binding results in high-affinity inhibition with slow dissociation kinetics, frequently leading to drug trapping and prolonged action potential duration (APD). This can predispose patients to arrhythmias, including Torsades de Pointes. Beyond cardiac drugs, there are several non-cardiac methanesulfonamide drugs that also block the hERG channel. This causes pro-arrhythmic side effects despite their primary indications. The clinical significance of these effects, especially in patients with impaired drug elimination, is that accumulation increases the risk of arrhythmia. The objective of forthcoming research endeavors is to mitigate hERG affinity, with the aim of reducing pro-arrhythmic risks while maintaining therapeutic efficacy. This means structural modifications that seek to remove or modify the methanesulfonamide group. Machine learning also emerged as promising tool for exploring drug–protein interactions. It is evident that the methanesulfonamide moiety plays a pivotal role in the structural basis of hERG blockade. However, it should be noted that this moiety does not necessarily represent a universal pharmacophore. This observation underscores the necessity for a nuanced approach in drug development, aimed at achieving a balance between efficacy and safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
- Doctoral School of Dental Sciences, University of Debrecen, H-4032 Debrecen, Hungary.
- Division of Sport Physiology, Department of Physiology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
- Department of Dental Physiology and Pharmacology, Faculty of Dentistry, University of Debrecen, H-4032 Debrecen, Hungary.
- Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
- Department of Basic Medical Sciences, Faculty of Dentistry, University of Debrecen, H-4032 Debrecen, Hungary.
ORCID-Profile: Zsigmond Máté Kovács, János Magyar, Tamás Bányász, Balázs Horváth, Gábor Balogh, Norbert Szentandrássy
Förderung
- National Research, Development and Innovation Office
- National Research Development and Innovation Office
- National Research, Development and Innovation Fund
- University of Debrecen Program for Scientific Publication
Zitieren
APA
Kovács, Z. M., Óvári, J., Magyar, J., Bányász, T., Nánási, P. P., Horváth, B., Balogh, G., & Szentandrássy, N. (2026). The Methanesulfonamide Group: Bright and Dark Sides of hERG Potassium Channel Inhibition. Pharmaceuticals, 19(6), 882. https://doi.org/10.3390/ph19060882
Vancouver
Kovács ZM, Óvári J, Magyar J, Bányász T, Nánási PP, Horváth B, et al. The Methanesulfonamide Group: Bright and Dark Sides of hERG Potassium Channel Inhibition. Pharmaceuticals. 2026;19(6):882. doi:10.3390/ph19060882
BibTeX
@article{Kovcs2026,
author = {Kovács, Zsigmond Máté and Óvári, József and Magyar, János and Bányász, Tamás and Nánási, Péter P and Horváth, Balázs and Balogh, Gábor and Szentandrássy, Norbert},
title = {The Methanesulfonamide Group: Bright and Dark Sides of hERG Potassium Channel Inhibition},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {882},
doi = {10.3390/ph19060882}
}
EUVIMED